Global CDMO Leverage mAbxience as a globally integrated biopharmaceutical CDMO with GMP-approved multi-product facilities in Europe and South America to offer contract development and manufacturing services to biosimilar and biologics clients seeking scalable production and regulatory aligned operations.

Biosimilar Focus Target pharmaceutical and biotech companies developing oncology and other biosimilar portfolios, highlighting mAbxience’s ongoing biosimilar programs and partnerships to position as a reliable manufacturing and development partner capable of accelerating time-to-market.

Strategic Partnerships Capitalize on established networks with 30+ partners and collaboration history with firms like Biosidus and Teva to pursue co-development or manufacturing partnerships, regional expansion projects, and supply agreements in new markets.

Regulatory Readiness Emphasize GMP approval from FDA, EMA, and other regulators to assure potential clients of compliant production, quality systems, and audit readiness, reducing their regulatory burden when outsourcing CDMO services.

Growth Signals Position mAbxience’s recent leadership changes, expanded client roster with Genedata Bioprocess, and continued pipeline development as indicators of scale-up potential, enabling up-selling of higher-value manufacturing services and platform investments.